Astellas/Cardiome Reports Positive Kynapid Phase III Study
This article was originally published in The Pink Sheet Daily
Executive Summary
Astellas awaits past-due decision from FDA on candidate that met primary endpoint in two Phase III trials.
You may also be interested in...
ANDROMEDA Strain: Full Data Published From Multaq Trial
Details show death rates that led to Sanofi study's halt.
ANDROMEDA Strain: Full Data Published From Multaq Trial
Details show death rates that led to Sanofi study's halt.
Sanofi-Aventis Heart Drug Multaq Back To FDA In Third Quarter
Follow-up ATHENA data bolsters NDA called “not approvable” in 2006.